Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease October 30, 2023 Read More »
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000 October 23, 2023 Read More »
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications August 29, 2023 Read More »
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement August 14, 2023 Read More »
Hemostemix Submits its Retrospective Heart Study to Leading Stem Cell Journal and has Prepared its CLI Phase II Clinical Trial Manuscript for Peer Review August 8, 2023 Read More »
